Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction

J M Berthiaume1, P J Oliveira, M W Fariss

  • 1Department of Biochemistry and Molecular Biology, University of Minnesota Medical School, Duluth, MN 55812, USA. jberthi1@d.umn.edu

Cardiovascular Toxicology
|October 26, 2005
PubMed

Insights

Dietary vitamin E (alpha-tocopherol) enriched cardiac membranes but did not prevent doxorubicin-induced cardiotoxicity. This suggests oxidative stress may not be the sole driver of this mitochondrial damage.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Doxorubicin (DOX) is a key antineoplastic agent.
  • DOX-induced cardiotoxicity is linked to oxidative stress impacting mitochondrial membranes.
  • Prior attempts using alpha-tocopherol (vitamin E) showed limited success due to delivery issues.

Purpose of the Study:

  • To determine if enriching cardiac membranes with alpha-tocopherol protects against DOX-induced mitochondrial cardiotoxicity.
  • To investigate the role of oxidative stress in DOX cardiotoxicity.

Main Methods:

  • Adult male Sprague-Dawley rats received weekly DOX injections.
  • Rats were fed either a standard diet or one supplemented with alpha-tocopherol succinate.
  • Histology, oxidized protein content, and mitochondrial calcium loading were assessed.

Main Results:

  • DOX treatment induced mitochondrial cardiomyopathy, evidenced by histopathology and reduced mitochondrial calcium capacity.
  • Alpha-tocopherol supplementation significantly enriched cardiac mitochondrial membranes (2-4 fold).
  • While tocopherol enrichment reduced oxidized cardiac proteins, it did not prevent mitochondrial dysfunction or cardiac damage.

Conclusions:

  • Dietary vitamin E supplementation enriches cardiac mitochondrial membranes with alpha-tocopherol.
  • This enrichment was insufficient to protect against DOX-induced mitochondrial cardiotoxicity.
  • Oxidative stress alone may not fully explain the persistent mitochondrial cardiomyopathy from long-term DOX therapy.